Chang Melissa I, Cohen Benjamin L, Greenstein Alexander J
Departments of *Surgery, and †Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.
Inflamm Bowel Dis. 2015 Jun;21(6):1472-7. doi: 10.1097/MIB.0000000000000362.
Anti-tumor necrosis factor therapy has revolutionized the treatment of Crohn's disease. Despite the increased use in the past decade and a half, a majority of patients with Crohn's disease with ultimately require operative management of their disease. No clear consensus has been made in the literature regarding the surgical outcomes in patients who have been exposed to anti-tumor necrosis factor therapy. This review highlights the most recent and relevant literature regarding the safety and effects of anti-tumor necrosis factor use in the perioperative period.
抗肿瘤坏死因子疗法彻底改变了克罗恩病的治疗方式。尽管在过去十五年中其使用有所增加，但大多数克罗恩病患者最终仍需要对其疾病进行手术治疗。关于接受过抗肿瘤坏死因子治疗的患者的手术结果，文献中尚未达成明确共识。本综述重点介绍了关于围手术期使用抗肿瘤坏死因子的安全性和效果的最新相关文献。
